Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2012 | Original investigation

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Authors: Tamio Teramoto, Kohji Shirai, Hiroyuki Daida, Nobuhiro Yamada

Published in: Cardiovascular Diabetology | Issue 1/2012

Abstract

Background

The hypoglycemic effect of bezafibrate is well established, but administration to a large population of patients with diabetes has not been reported. We investigated glycemic control, relationship between lipid metabolism and HbA1c, and safety in diabetic patients treated with bezafibrate.

Methods

A prospective, observational analysis was conducted on 6,407 dyslipidemic patients suffering from diabetes or hyperglycemia who had not received bezafibrate previously. Subanalyses were performed on the concomitant use of diabetes drugs, diabetes duration, and baseline HbA1c levels.

Results

Bezafibrate significantly decreased HbA1c irrespective of concomitant use of other diabetes drugs in a baseline-HbA1c-dependent manner, with patients with a shorter diabetes duration showing a greater decrease in HbA1c than those with longer-term disease. The rate of change in triglyceride levels was significantly associated with that in HbA1c. Adverse drug reactions occurred in 306 patients (5.1%), of which reactions in 289 were not severe (94.4%).

Conclusions

Bezafibrate significantly improved HbA1c in patients with diabetes given individualized treatment. Bezafibrate may offer clinicians an improved modality for the amelioration of disease course and improvement of outcome in these patients.

Available only for authorised users

Chan JC, Malik V, Jia W, et al: Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009, 301: 2129-2140.CrossRefPubMed

Haffner SM, Lehto S, Rönnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234.CrossRefPubMed

Stratton IM, Adler AI, Neil HA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321: 405-412.PubMedCentralCrossRefPubMed

Uusitupa MI, Niskanen LK, Siitonen O, et al: 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in noninsulin dependent diabetic and non-diabetic subjects. Circulation. 1990, 82: 27-36.CrossRefPubMed

Lehto S, Rönnemaa T, Haffner SM, et al: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997, 46: 1354-1359.CrossRefPubMed

Wahl P, Hasslacher Ch, Lang PD, et al: Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia. Dtsch med Wochenschr. 1978, 103: 1233-1237.CrossRefPubMed

Bruneder H, Klein HJ: Treatment of hyperlipoproteinaemia in diabetic patients. Dtsch Med Wochenschr. 1981, 106: 1653-1656.CrossRefPubMed

Tenenbaum A, Fisman EZ, Motro M, et al: Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. Adv Cardiol. 2008, 45: 127-153.CrossRefPubMed

Krey G, Braissant O, L'Horset F, et al: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997, 11: 779-791.CrossRefPubMed

10.

Moya-Camarena SY, Van den Heuvel JP, Belury MA: Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats. Biochim Biophys Acta. 1999, 1436: 331-342.CrossRefPubMed

11.

Peters JM, Aoyama T, Burns AM, et al: Bezafibrate is a dual ligand for PPAR alpha and PPAR beta: studies using null mice. Biochim Biophys Acta. 2003, 1632: 80-89.CrossRefPubMed

12.

Tenenbaum A, Motro M, Fisman E, Review Z: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005, 4: 14-18.PubMedCentralCrossRefPubMed

13.

Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000, 43: 527-550.CrossRefPubMed

14.

Jones IR, Swai A, Taylor R, et al: Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care. 1990, 13: 855-863.CrossRefPubMed

15.

Taniguchi A, Fukudhima M, Sakai M, et al: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism. 2001, 50: 477-480.CrossRefPubMed

16.

Ogawa S, Takeuchi K, Sugimura K, et al: Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism. 2000, 49: 331-334.CrossRefPubMed

17.

Elkeles R: Fibrates: old drugs with a new role in type 2 diabetes prevention?. Br J Diabetes Vasc Dis. 2011, 11: 4-9.CrossRef

18.

Friedewald WT, Levy R, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed

19.

The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010, 53: 450-467. in Japanese

20.

Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996, 3: 213-219.CrossRefPubMed

21.

Khan HA, Sobki SH, Khan SA: Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007, 7: 24-29.CrossRefPubMed

22.

Zhang L, Qiao Q, Tuomilehto J, et al: Blood lipid levels in relation to glucose status in seven populations of Asian origin without a prior history of diabetes: the DECODA study. Diabetes Metab Res Rev. 2009, 25: 549-557.CrossRefPubMed

23.

Baigent C, Keech A, Kearney PM, et al: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005, 366: 1267-1278.CrossRefPubMed

24.

Mills EJ, Rachlis B, Wu P, Devereaux PJ, et al: Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008, 52: 1769-1781.CrossRefPubMed

25.

Brugts JJ, Yetgin T, Hoeks SE, et al: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009, 338: b2376.PubMedCentralCrossRefPubMed

26.

Baigent C, Blackwell L, Emberson J, et al: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010, 376: 1670-1681.CrossRefPubMed

27.

Mazza F, Stefanutti C, Di Giacomo S, et al: Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2008, 8: 265-270.CrossRefPubMed

28.

Saito Y, Yamada N, Shirai K, et al: Effect of rosuvastatin 5-20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis. 2007, 194: 505-511.CrossRefPubMed

29.

Jun M, Foote C, Lv J, et al: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010, 375: 1875-1884.CrossRefPubMed

30.

ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010, 362: 1563-1574.CrossRef

31.

Tenenbaum A, Fisman EZ: "If it ain't broke, don't fix it": a commentary on the positive- negative results of the ACCORD Lipid study. Cardiovasc Diabetol. 2010, 9: 24-28.PubMedCentralCrossRefPubMed

32.

The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000, 102: 21-27.CrossRef

33.

The ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010, 362: 24-29. supplementary Appendix1. NEJM.orgCrossRef

34.

FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005, 366: 1849-1861.CrossRef

35.

Sattar N, Preiss D, Murray HM, et al: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010, 375: 735-742.CrossRefPubMed

36.

Rajapathak SN, Kumbhani DJ, Crandall J, et al: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009, 32: 1924-1929.CrossRef

37.

Elkeles RS, Diamond JR, Poulter C, et al: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998, 21: 641-648.CrossRefPubMed

38.

Tenenbaum A, Motro M, Fisman EZ, et al: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004, 109: 2197-2202.CrossRefPubMed

39.

Bays H, Mandarino L, DeFronzo RA: Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004, 89: 463-478.CrossRefPubMed

40.

Tremblay-Mercier J, Tessier D, Plourde M, et al: Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects. J Pharmacol Exp Ther. 2010, 334: 341-346.CrossRefPubMed

41.

Cabrero A, Alegret M, Sánchez RM, et al: Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes. 2001, 50: 1883-1890.CrossRefPubMed

42.

Nagasawa T, Inada Y, Nakano S, et al: Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR delta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol. 2006, 536: 182-191.CrossRefPubMed

43.

Van der Zijl NJ, Goossens GH, Moors CC, et al: Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab. 2011, 96: 459-467.CrossRefPubMed

44.

Fernandes-Santos C, Evangelista Carneiro R, de Souza Mendonca L, et al: Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. Pancreas. 2009, 38: e80-e86.CrossRefPubMed

45.

Betteridge DJ, O'Bryan-Tear CG: Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. Postgrad Med J. 1996, 72: 739-743.PubMedCentralCrossRefPubMed

46.

Beggs PW, Clark DW, Williams SM, et al: A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). Br J Clin Pharmacol. 1999, 47: 99-104.PubMedCentralCrossRefPubMed

47.

Nathan DM, Buse JB, Davidson MB, et al: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006, 29: 1963-1972.CrossRefPubMed

48.

Sone H, Ito H, Ohashi Y, et al: Obesity and type 2 diabetes in Japanese patients. Lancet. 2003, 361: 85.CrossRefPubMed

49.

John WG, Mosca A, Weykamp C, et al: HbA1c standardisation: history, science and politics. Clin Biochem Rev. 2007, 28: 163-168.PubMedCentralPubMed

50.

Nihei T, Saitou T, Yokoyama T, et al: Evaluation for commutability of hemoglobin A1c measurement by IFCC calibration. JJCLA. 2011, 36: 18-25. in Japanese

Title: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
Authors: Tamio Teramoto
Kohji Shirai
Hiroyuki Daida
Nobuhiro Yamada
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-11-29

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Using the spring constant method to analyze arterial elasticity in type 2 diabeticpatients

High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis

Effects of olmesartan on arterial stiffness in rats with chronic renal failure

Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome

Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning

The association of insulin resistance and carotid atherosclerosis with thigh and calf circumference in patients with type 2 diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page